Transition to a mesenchymal state in neuroblastoma confers resistance to anti-GD2 antibody via reduced expression of ST8SIA1
Immunotherapy with anti-GD2 antibodies has advanced the treatment of children with high-
risk neuroblastoma, but nearly half of patients relapse, and little is known about mechanisms …
risk neuroblastoma, but nearly half of patients relapse, and little is known about mechanisms …
Anti-GD2 synergizes with CD47 blockade to mediate tumor eradication
The disialoganglioside GD2 is overexpressed on several solid tumors, and monoclonal
antibodies targeting GD2 have substantially improved outcomes for children with high-risk …
antibodies targeting GD2 have substantially improved outcomes for children with high-risk …
Advances in anti-GD2 immunotherapy for treatment of high-risk neuroblastoma
J Voeller, PM Sondel - Journal of pediatric hematology/oncology, 2019 - journals.lww.com
Neuroblastoma (NBL) is the most common extracranial solid tumor in pediatrics, yet overall
survival is poor for high-risk cases. Immunotherapy regimens using a tumor-selective …
survival is poor for high-risk cases. Immunotherapy regimens using a tumor-selective …
Disialoganglioside directed immunotherapy of neuroblastoma
S Modak, NKV Cheung - Cancer investigation, 2007 - Taylor & Francis
Achieving a cure for metastatic neuroblastoma remains a challenge despite sensitivity to
chemotherapy and radiotherapy. Most patients achieve remission, but a failure to eliminate …
chemotherapy and radiotherapy. Most patients achieve remission, but a failure to eliminate …
Mesenchymal and adrenergic cell lineage states in neuroblastoma possess distinct immunogenic phenotypes
Apart from the anti-GD2 antibody, immunotherapy for neuroblastoma has had limited
success due to immune evasion mechanisms, coupled with an incomplete understanding of …
success due to immune evasion mechanisms, coupled with an incomplete understanding of …
[HTML][HTML] Polymorphonuclear myeloid-derived suppressor cells impair the anti-tumor efficacy of GD2. CAR T-cells in patients with neuroblastoma
N Tumino, G Weber, F Besi, F Del Bufalo… - Journal of hematology & …, 2021 - Springer
The outcome of patients affected by high-risk or metastatic neuroblastoma (NB) remains
grim, with≥ 50% of the children experiencing relapse or progression of the disease despite …
grim, with≥ 50% of the children experiencing relapse or progression of the disease despite …
A pilot trial of humanized anti-GD2 monoclonal antibody (hu14. 18K322A) with chemotherapy and natural killer cells in children with recurrent/refractory …
SM Federico, MB McCarville, BL Shulkin… - Clinical Cancer …, 2017 - AACR
Abstract Purpose: Anti-GD2 mAbs, acting via antibody-dependent cell-mediated cytotoxicity,
may enhance the effects of chemotherapy. This pilot trial investigated a fixed dose of a …
may enhance the effects of chemotherapy. This pilot trial investigated a fixed dose of a …
Immunotherapy of neuroblastoma: facts and hopes
While the adoption of multimodal therapy including surgery, radiation, and aggressive
combination chemotherapy has improved outcomes for many children with high-risk …
combination chemotherapy has improved outcomes for many children with high-risk …
[HTML][HTML] Anti-GD2 strategy in the treatment of neuroblastoma
The prognosis for advanced neuroblastoma remains poor with high risk of recurrence after
consolidation. Therapies based on monoclonal antibodies that specifically target …
consolidation. Therapies based on monoclonal antibodies that specifically target …
NK cells engineered to express a GD2‐specific antigen receptor display built‐in ADCC‐like activity against tumour cells of neuroectodermal origin
R Esser, T Müller, D Stefes, S Kloess… - Journal of cellular …, 2012 - Wiley Online Library
Abstract Treatment of high‐risk neuroblastoma (NB) represents a major challenge in
paediatric oncology. Alternative therapeutic strategies include antibodies targeting the …
paediatric oncology. Alternative therapeutic strategies include antibodies targeting the …